Accelerate Gene Editing Discoveries
with Confidence
Perform streamlined gene editing validation with our single-mismatch precision technology
The era of Cell & Gene Therapy is here! CRISPR-Cas and other groundbreaking gene-editing technologies are revolutionizing the field, with more therapies steadily advancing to clinical use. At Countagen, we are commited to empowering these breakthroughs and accelerating the journey from discovery to practical use. By redefining and streamlining validation methods, we are committed to transform the pace of development for these cutting-edge treatments.
Our flagship product, GeneAbacus, empowers researchers with rapid and streamlined gene editing efficiency quantification. Designed for in-house use with standard laboratory equipment, GeneAbacus delivers precise, quantitative, and actionable data within just five hours, accelerating the pace of discovery and development of Cell & Gene Therapies.
Ensuring Responsible Gene Editing
The rapid pace of gene editing breakthroughs requires a parallel focus on responsible application. Precise validation of gene editing efficiency and specificity is critical for several reasons:
- Safety: Ensuring edits occur at the intended location and do not introduce unintended changes is crucial for patient safety.
- Efficacy: Understanding the editing efficiency allows researchers to optimize protocols and maximize therapeutic effects.
- Reproducibility: Reliable analysis methods are essential for replicating results and advancing research.
Current Validation Methods: Bottlenecks in Progress
Traditional gene editing validation methods often present significant challenges:
- Fragmented and Time-consuming workflows: Weeks of analysis & dependence on external services can significantly delay validation of single targets.
- Target-by-target optimization: Every new target requires dedicated optimization efforts that consume time & resources and also results in lack of standardization.
- Limited precision: Current methods for rapid validation lack single-nucleotide precision, making it difficult to accurately assess editing outcomes.
These limitations hinder the progress of gene editing innovation and ultimately slow down the development of potentially life-saving therapies.
Streamlining Discoveries with GeneAbacus
Countagen is invested in streamlining gene editing innovation through a proprietary technology for edit validation. Our flagship product, GeneAbacus, addresses the limitations of traditional methods by offering:
- Rapid Turnaround Time: Obtain accurate results within a single day, significantly accelerating timelines.
- Single-Nucleotide Precision: GeneAbacus utilizes padlock probes and rolling circle amplification to achieve single-nucleotide precision, providing the confidence you need in your validation results.
- Simplified Workflow: Seamlessly integrate GeneAbacus into your existing laboratory workflow. The assay requires minimal hands-on time and is compatible with standard lab equipment.
Our Technology: A Catalyst for Progress
By empowering researchers with a faster, more reliable, and user-friendly solution for gene editing validation, GeneAbacus is paving the way for advancements in gene editing research and development.
- Accelerate the development of new treatments: Faster validation allows researchers to optimize protocols and move towards clinical applications quickly.
- Enhance the safety and efficacy of therapies: Precise analysis ensures edits occur at the intended location and with optimal efficiency, contributing to safer and more effective treatments.
- Drive responsible gene editing practices: Reliable data informs decision-making and promotes responsible application of this powerful technology.
Join Us in Shaping the Future of Healthcare
Countagen is dedicated to working alongside researchers to unlock the full potential of gene editing. We are committed to accelerating progress toward cell and gene therapy development.
Check out our FAQ to learn more about how we can support your research and development needs.
Subscribe to Our Newsletter